HER2-Positive Breast Cancer Market - Global Outlook and Forecast 2022-2028

March 2022 | 105 pages | ID: H03B198E9FE0EN
Market Monitor Global

Abstracts

HER2, also known as human epidermal growth factor receptor 2, is an important prognostic factor for breast cancer.HER2 is also expressed on the surface of some normal cells in the body.Her2-positive breast cancer is characterized by strong invasion, more recurrence and metastasis, and short disease-free survival.

This report contains market size and forecasts of HER2-Positive Breast Cancer in Global, including the following market information:

Global HER2-Positive Breast Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global HER2-Positive Breast Cancer market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Grifola Frondosa Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of HER2-Positive Breast Cancer include Pfizer (Pharmacia and Upjohn Company), Novartis, AstraZeneca Pharmaceuticals, Eli Lilly, Roche Group, Merck, Jiangsu HengRui Medicine, Odonate Therapeutics and Radius Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the HER2-Positive Breast Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global HER2-Positive Breast Cancer Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global HER2-Positive Breast Cancer Market Segment Percentages, by Type, 2021 (%)

• Grifola Frondosa
• Surgery
• Radiation and Chemotherapy
• Endocrine Therapy
• Molecular Targeted Therapy

Global HER2-Positive Breast Cancer Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global HER2-Positive Breast Cancer Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Specialist Clinic
• Biotechnology and Pharmaceutical Companies
• Research and Academic Institutions
• Other

Global HER2-Positive Breast Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global HER2-Positive Breast Cancer Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies HER2-Positive Breast Cancer revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies HER2-Positive Breast Cancer revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer (Pharmacia and Upjohn Company)
• Novartis
• AstraZeneca Pharmaceuticals
• Eli Lilly
• Roche Group
• Merck
• Jiangsu HengRui Medicine
• Odonate Therapeutics
• Radius Pharmaceuticals
• Immunomedics
• Syndax Pharmaceuticals
• Bayer
• Eagle Pharmaceuticals
• Merrimack Pharmaceuticals
• GlaxoSmithKline
• Millennium Pharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 HER2-Positive Breast Cancer Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global HER2-Positive Breast Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL HER2-POSITIVE BREAST CANCER OVERALL MARKET SIZE

2.1 Global HER2-Positive Breast Cancer Market Size: 2021 VS 2028
2.2 Global HER2-Positive Breast Cancer Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top HER2-Positive Breast Cancer Players in Global Market
3.2 Top Global HER2-Positive Breast Cancer Companies Ranked by Revenue
3.3 Global HER2-Positive Breast Cancer Revenue by Companies
3.4 Top 3 and Top 5 HER2-Positive Breast Cancer Companies in Global Market, by Revenue in 2021
3.5 Global Companies HER2-Positive Breast Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 HER2-Positive Breast Cancer Players in Global Market
  3.6.1 List of Global Tier 1 HER2-Positive Breast Cancer Companies
  3.6.2 List of Global Tier 2 and Tier 3 HER2-Positive Breast Cancer Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global HER2-Positive Breast Cancer Market Size Markets, 2021 & 2028
  4.1.2 Grifola Frondosa
  4.1.3 Surgery
  4.1.4 Radiation and Chemotherapy
  4.1.5 Endocrine Therapy
  4.1.6 Molecular Targeted Therapy
4.2 By Type - Global HER2-Positive Breast Cancer Revenue & Forecasts
  4.2.1 By Type - Global HER2-Positive Breast Cancer Revenue, 2017-2022
  4.2.2 By Type - Global HER2-Positive Breast Cancer Revenue, 2023-2028
  4.2.3 By Type - Global HER2-Positive Breast Cancer Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global HER2-Positive Breast Cancer Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Specialist Clinic
  5.1.4 Biotechnology and Pharmaceutical Companies
  5.1.5 Research and Academic Institutions
  5.1.6 Other
5.2 By Application - Global HER2-Positive Breast Cancer Revenue & Forecasts
  5.2.1 By Application - Global HER2-Positive Breast Cancer Revenue, 2017-2022
  5.2.2 By Application - Global HER2-Positive Breast Cancer Revenue, 2023-2028
  5.2.3 By Application - Global HER2-Positive Breast Cancer Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global HER2-Positive Breast Cancer Market Size, 2021 & 2028
6.2 By Region - Global HER2-Positive Breast Cancer Revenue & Forecasts
  6.2.1 By Region - Global HER2-Positive Breast Cancer Revenue, 2017-2022
  6.2.2 By Region - Global HER2-Positive Breast Cancer Revenue, 2023-2028
  6.2.3 By Region - Global HER2-Positive Breast Cancer Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America HER2-Positive Breast Cancer Revenue, 2017-2028
  6.3.2 US HER2-Positive Breast Cancer Market Size, 2017-2028
  6.3.3 Canada HER2-Positive Breast Cancer Market Size, 2017-2028
  6.3.4 Mexico HER2-Positive Breast Cancer Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe HER2-Positive Breast Cancer Revenue, 2017-2028
  6.4.2 Germany HER2-Positive Breast Cancer Market Size, 2017-2028
  6.4.3 France HER2-Positive Breast Cancer Market Size, 2017-2028
  6.4.4 U.K. HER2-Positive Breast Cancer Market Size, 2017-2028
  6.4.5 Italy HER2-Positive Breast Cancer Market Size, 2017-2028
  6.4.6 Russia HER2-Positive Breast Cancer Market Size, 2017-2028
  6.4.7 Nordic Countries HER2-Positive Breast Cancer Market Size, 2017-2028
  6.4.8 Benelux HER2-Positive Breast Cancer Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia HER2-Positive Breast Cancer Revenue, 2017-2028
  6.5.2 China HER2-Positive Breast Cancer Market Size, 2017-2028
  6.5.3 Japan HER2-Positive Breast Cancer Market Size, 2017-2028
  6.5.4 South Korea HER2-Positive Breast Cancer Market Size, 2017-2028
  6.5.5 Southeast Asia HER2-Positive Breast Cancer Market Size, 2017-2028
  6.5.6 India HER2-Positive Breast Cancer Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America HER2-Positive Breast Cancer Revenue, 2017-2028
  6.6.2 Brazil HER2-Positive Breast Cancer Market Size, 2017-2028
  6.6.3 Argentina HER2-Positive Breast Cancer Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa HER2-Positive Breast Cancer Revenue, 2017-2028
  6.7.2 Turkey HER2-Positive Breast Cancer Market Size, 2017-2028
  6.7.3 Israel HER2-Positive Breast Cancer Market Size, 2017-2028
  6.7.4 Saudi Arabia HER2-Positive Breast Cancer Market Size, 2017-2028
  6.7.5 UAE HER2-Positive Breast Cancer Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer (Pharmacia and Upjohn Company)
  7.1.1 Pfizer (Pharmacia and Upjohn Company) Corporate Summary
  7.1.2 Pfizer (Pharmacia and Upjohn Company) Business Overview
  7.1.3 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Major Product Offerings
  7.1.4 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.1.5 Pfizer (Pharmacia and Upjohn Company) Key News
7.2 Novartis
  7.2.1 Novartis Corporate Summary
  7.2.2 Novartis Business Overview
  7.2.3 Novartis HER2-Positive Breast Cancer Major Product Offerings
  7.2.4 Novartis HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.2.5 Novartis Key News
7.3 AstraZeneca Pharmaceuticals
  7.3.1 AstraZeneca Pharmaceuticals Corporate Summary
  7.3.2 AstraZeneca Pharmaceuticals Business Overview
  7.3.3 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Major Product Offerings
  7.3.4 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.3.5 AstraZeneca Pharmaceuticals Key News
7.4 Eli Lilly
  7.4.1 Eli Lilly Corporate Summary
  7.4.2 Eli Lilly Business Overview
  7.4.3 Eli Lilly HER2-Positive Breast Cancer Major Product Offerings
  7.4.4 Eli Lilly HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.4.5 Eli Lilly Key News
7.5 Roche Group
  7.5.1 Roche Group Corporate Summary
  7.5.2 Roche Group Business Overview
  7.5.3 Roche Group HER2-Positive Breast Cancer Major Product Offerings
  7.5.4 Roche Group HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.5.5 Roche Group Key News
7.6 Merck
  7.6.1 Merck Corporate Summary
  7.6.2 Merck Business Overview
  7.6.3 Merck HER2-Positive Breast Cancer Major Product Offerings
  7.6.4 Merck HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.6.5 Merck Key News
7.7 Jiangsu HengRui Medicine
  7.7.1 Jiangsu HengRui Medicine Corporate Summary
  7.7.2 Jiangsu HengRui Medicine Business Overview
  7.7.3 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Major Product Offerings
  7.7.4 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.7.5 Jiangsu HengRui Medicine Key News
7.8 Odonate Therapeutics
  7.8.1 Odonate Therapeutics Corporate Summary
  7.8.2 Odonate Therapeutics Business Overview
  7.8.3 Odonate Therapeutics HER2-Positive Breast Cancer Major Product Offerings
  7.8.4 Odonate Therapeutics HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.8.5 Odonate Therapeutics Key News
7.9 Radius Pharmaceuticals
  7.9.1 Radius Pharmaceuticals Corporate Summary
  7.9.2 Radius Pharmaceuticals Business Overview
  7.9.3 Radius Pharmaceuticals HER2-Positive Breast Cancer Major Product Offerings
  7.9.4 Radius Pharmaceuticals HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.9.5 Radius Pharmaceuticals Key News
7.10 Immunomedics
  7.10.1 Immunomedics Corporate Summary
  7.10.2 Immunomedics Business Overview
  7.10.3 Immunomedics HER2-Positive Breast Cancer Major Product Offerings
  7.10.4 Immunomedics HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.10.5 Immunomedics Key News
7.11 Syndax Pharmaceuticals
  7.11.1 Syndax Pharmaceuticals Corporate Summary
  7.11.2 Syndax Pharmaceuticals Business Overview
  7.11.3 Syndax Pharmaceuticals HER2-Positive Breast Cancer Major Product Offerings
  7.11.4 Syndax Pharmaceuticals HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.11.5 Syndax Pharmaceuticals Key News
7.12 Bayer
  7.12.1 Bayer Corporate Summary
  7.12.2 Bayer Business Overview
  7.12.3 Bayer HER2-Positive Breast Cancer Major Product Offerings
  7.12.4 Bayer HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.12.5 Bayer Key News
7.13 Eagle Pharmaceuticals
  7.13.1 Eagle Pharmaceuticals Corporate Summary
  7.13.2 Eagle Pharmaceuticals Business Overview
  7.13.3 Eagle Pharmaceuticals HER2-Positive Breast Cancer Major Product Offerings
  7.13.4 Eagle Pharmaceuticals HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.13.5 Eagle Pharmaceuticals Key News
7.14 Merrimack Pharmaceuticals
  7.14.1 Merrimack Pharmaceuticals Corporate Summary
  7.14.2 Merrimack Pharmaceuticals Business Overview
  7.14.3 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Major Product Offerings
  7.14.4 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.14.5 Merrimack Pharmaceuticals Key News
7.15 GlaxoSmithKline
  7.15.1 GlaxoSmithKline Corporate Summary
  7.15.2 GlaxoSmithKline Business Overview
  7.15.3 GlaxoSmithKline HER2-Positive Breast Cancer Major Product Offerings
  7.15.4 GlaxoSmithKline HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.15.5 GlaxoSmithKline Key News
7.16 Millennium Pharmaceuticals
  7.16.1 Millennium Pharmaceuticals Corporate Summary
  7.16.2 Millennium Pharmaceuticals Business Overview
  7.16.3 Millennium Pharmaceuticals HER2-Positive Breast Cancer Major Product Offerings
  7.16.4 Millennium Pharmaceuticals HER2-Positive Breast Cancer Revenue in Global Market (2017-2022)
  7.16.5 Millennium Pharmaceuticals Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. HER2-Positive Breast Cancer Market Opportunities & Trends in Global Market
Table 2. HER2-Positive Breast Cancer Market Drivers in Global Market
Table 3. HER2-Positive Breast Cancer Market Restraints in Global Market
Table 4. Key Players of HER2-Positive Breast Cancer in Global Market
Table 5. Top HER2-Positive Breast Cancer Players in Global Market, Ranking by Revenue (2021)
Table 6. Global HER2-Positive Breast Cancer Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global HER2-Positive Breast Cancer Revenue Share by Companies, 2017-2022
Table 8. Global Companies HER2-Positive Breast Cancer Product Type
Table 9. List of Global Tier 1 HER2-Positive Breast Cancer Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 HER2-Positive Breast Cancer Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global HER2-Positive Breast Cancer Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - HER2-Positive Breast Cancer Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - HER2-Positive Breast Cancer Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global HER2-Positive Breast Cancer Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - HER2-Positive Breast Cancer Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - HER2-Positive Breast Cancer Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global HER2-Positive Breast Cancer Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global HER2-Positive Breast Cancer Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global HER2-Positive Breast Cancer Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America HER2-Positive Breast Cancer Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe HER2-Positive Breast Cancer Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia HER2-Positive Breast Cancer Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America HER2-Positive Breast Cancer Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa HER2-Positive Breast Cancer Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer (Pharmacia and Upjohn Company) Corporate Summary
Table 31. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Product Offerings
Table 32. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 33. Novartis Corporate Summary
Table 34. Novartis HER2-Positive Breast Cancer Product Offerings
Table 35. Novartis HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 36. AstraZeneca Pharmaceuticals Corporate Summary
Table 37. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Product Offerings
Table 38. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 39. Eli Lilly Corporate Summary
Table 40. Eli Lilly HER2-Positive Breast Cancer Product Offerings
Table 41. Eli Lilly HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 42. Roche Group Corporate Summary
Table 43. Roche Group HER2-Positive Breast Cancer Product Offerings
Table 44. Roche Group HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 45. Merck Corporate Summary
Table 46. Merck HER2-Positive Breast Cancer Product Offerings
Table 47. Merck HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 48. Jiangsu HengRui Medicine Corporate Summary
Table 49. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Product Offerings
Table 50. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 51. Odonate Therapeutics Corporate Summary
Table 52. Odonate Therapeutics HER2-Positive Breast Cancer Product Offerings
Table 53. Odonate Therapeutics HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 54. Radius Pharmaceuticals Corporate Summary
Table 55. Radius Pharmaceuticals HER2-Positive Breast Cancer Product Offerings
Table 56. Radius Pharmaceuticals HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 57. Immunomedics Corporate Summary
Table 58. Immunomedics HER2-Positive Breast Cancer Product Offerings
Table 59. Immunomedics HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 60. Syndax Pharmaceuticals Corporate Summary
Table 61. Syndax Pharmaceuticals HER2-Positive Breast Cancer Product Offerings
Table 62. Syndax Pharmaceuticals HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 63. Bayer Corporate Summary
Table 64. Bayer HER2-Positive Breast Cancer Product Offerings
Table 65. Bayer HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 66. Eagle Pharmaceuticals Corporate Summary
Table 67. Eagle Pharmaceuticals HER2-Positive Breast Cancer Product Offerings
Table 68. Eagle Pharmaceuticals HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 69. Merrimack Pharmaceuticals Corporate Summary
Table 70. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Product Offerings
Table 71. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 72. GlaxoSmithKline Corporate Summary
Table 73. GlaxoSmithKline HER2-Positive Breast Cancer Product Offerings
Table 74. GlaxoSmithKline HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)
Table 75. Millennium Pharmaceuticals Corporate Summary
Table 76. Millennium Pharmaceuticals HER2-Positive Breast Cancer Product Offerings
Table 77. Millennium Pharmaceuticals HER2-Positive Breast Cancer Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. HER2-Positive Breast Cancer Segment by Type in 2021
Figure 2. HER2-Positive Breast Cancer Segment by Application in 2021
Figure 3. Global HER2-Positive Breast Cancer Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global HER2-Positive Breast Cancer Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global HER2-Positive Breast Cancer Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by HER2-Positive Breast Cancer Revenue in 2021
Figure 8. By Type - Global HER2-Positive Breast Cancer Revenue Market Share, 2017-2028
Figure 9. By Application - Global HER2-Positive Breast Cancer Revenue Market Share, 2017-2028
Figure 10. By Region - Global HER2-Positive Breast Cancer Revenue Market Share, 2017-2028
Figure 11. By Country - North America HER2-Positive Breast Cancer Revenue Market Share, 2017-2028
Figure 12. US HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 13. Canada HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe HER2-Positive Breast Cancer Revenue Market Share, 2017-2028
Figure 16. Germany HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 17. France HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 19. Italy HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 20. Russia HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia HER2-Positive Breast Cancer Revenue Market Share, 2017-2028
Figure 24. China HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 25. Japan HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 28. India HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America HER2-Positive Breast Cancer Revenue Market Share, 2017-2028
Figure 30. Brazil HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa HER2-Positive Breast Cancer Revenue Market Share, 2017-2028
Figure 33. Turkey HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 34. Israel HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 36. UAE HER2-Positive Breast Cancer Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Eli Lilly HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Roche Group HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Merck HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Odonate Therapeutics HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Radius Pharmaceuticals HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Immunomedics HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Syndax Pharmaceuticals HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Bayer HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Eagle Pharmaceuticals HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. GlaxoSmithKline HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Millennium Pharmaceuticals HER2-Positive Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)